首页> 外文期刊>Modern Pathology >HPV L1 detection discriminates cervical precancer from transient HPV infection: a prospective international multicenter study
【24h】

HPV L1 detection discriminates cervical precancer from transient HPV infection: a prospective international multicenter study

机译:HPV L1检测可将宫颈癌与短暂性HPV感染区分开来:一项前瞻性国际多中心研究

获取原文
           

摘要

The benefits of cytology-based cervical cancer screening programs in reducing morbidity and mortality are well recognized. Especially, overtreatment of human papillomavirus (HPV) high-risk positive early dysplastic lesions may have a negative impact on reproductive outcomes for fertile women. To optimize the clinical management an objective standard is needed to distinguish precancer that requires treatment, from spontaneously resolving HPV infections. In the current study, we examined the prognostic relevance of HPV-L1 capsid protein analysis with Cytoactiv in an international prospective multicenter study including 908 HPV high-risk positive early dysplastic lesions (LSIL/HSIL) during a follow-up period of 54 months. The clinical end points of the study were histologically confirmed CIN3+ as progression, CIN1/2 for stable disease and repeated negative Pap smears as spontaneous clinical remission. The difference of the clinical outcome of HPV-L1-negative and HPV-L1-positive cases was statistically highly significant (P-value<0.0001) independent of the classification as mild dysplasia (LSIL) and moderate dysplasia (HSIL). Of the HPV-L1-negative HPV high-risk positive mild/moderate dysplasias 84% progressed to CIN3, as compared with only 20% of the HPV-L1-positive cases. The data from our study show that HPV-L1 detection allows to identify transient HPV infections and precancerous lesions within the group of HPV high-risk positive early dysplastic lesions. The high progression rate of HPV-L1-negative mild and moderate dysplasia emphasizes the precancerous nature of these lesions. A close follow-up with colposcopy and histological evaluation is advisable and removal of these lesions should be considered. The low malignant potential of HPV-L1-positive cases, however, indicates transient HPV infection, justifying a watch and wait strategy with cytological follow-up, thus preventing overtreatment especially for women in their reproductive age.
机译:基于细胞学的子宫颈癌筛查计划在降低发病率和死亡率方面的优势已广为人知。特别是,过度治疗人乳头瘤病毒(HPV)高风险阳性早期发育异常病变可能对可育妇女的生殖结局产生负面影响。为了优化临床管理,需要一个客观的标准来区分需要治疗的癌症和自发解决HPV感染。在本研究中,我们在一项国际前瞻性多中心研究中检查了HPV-L1衣壳蛋白分析与Cytoactiv的预后相关性,该研究包括在54个月的随访期内908例HPV高危阳性早期发育异常性病变(LSIL / HSIL)。该研究的临床终点在组织学上被确认为CIN3 +进展,CIN1 / 2为稳定疾病,反复阴性涂片涂片为自发性临床缓解。 HPV-L1阴性和HPV-L1阳性病例的临床结局差异在统计学上具有显着显着性(P值<0.0001),而与轻度不典型增生(LSIL)和中度不典型增生(HSIL)无关。 HPV-L1阴性HPV高危阳性轻度/中度不典型增生发展为CIN3,而HPV-L1阳性病例仅为20%。我们的研究数据表明,HPV-L1检测可在HPV高危阳性早期发育异常性病变组中鉴定出短暂性HPV感染和癌前病变。 HPV-L1阴性和中度不典型增生的高进展率强调了这些病变的癌前性质。建议进行阴道镜和组织学评估的密切随访,并应考虑切除这些病变。但是,HPV-L1阳性病例的低恶性潜能表明HPV暂时性感染,需要采取细胞学随访的观察和等待策略,从而防止过度治疗,尤其是对于育龄妇女。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号